CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Taipei, Taiwan and 145 other locations
doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...
Phase 2
Taipei City, Taiwan and 41 other locations
of belantamab (bela) in participants with relapsed or refractory multiple myeloma (RRMM).* Part 2: The primary purpose of this part...
Phase 1
Taipei, Taiwan and 16 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Taipei, Taiwan and 218 other locations
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...
Phase 3
Taipei City, Taipei, Taiwan and 71 other locations
combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines of ...
Phase 2
Taipei, Taiwan and 17 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
Taipei, Taiwan and 269 other locations
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple...
Phase 2
Taipei, Taiwan and 97 other locations
antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratum ...
Phase 3
Taipei, Taiwan and 262 other locations
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells c...
Phase 3
Taipei, Taiwan and 72 other locations
Clinical trials
Research sites
Resources
Legal